First phase of ADVANTAGE AF clinical trial achieves safety and effectiveness endpoints for treatment of drug-resistant, symptomatic, persistent atrial fibrillation with the FARAPULSE™ Pulsed Field ...

MARLBOROUGH, Mass., May 22, 2019 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) has initiated the OPTION trial to compare safety and effectiveness of the next-generation WATCHMAN FLX™ left ...

The OPTION trial showed equivalence between Watchman FLX and oral anticoagulation in preventing stroke, systemic embolism, and all-cause death post-ablation. Subgroup analyses revealed consistent ...

Please provide your email address to receive an email when new articles are posted on . OPTION is a head-to-head trial of left atrial appendage closure with Watchman FLX vs. anticoagulation after ...

FALL RIVER, Mass. (WPRI) — A heart procedure that’s part of a new study looking at ways to fix atrial fibrillation without damaging healthy heart cells was done for the first time in the world at ...

Applying radiofrequency (RF) energy to the left atrial appendage (LAA) in patients with residual leak after Watchman (Boston Scientific) implantation might be a viable way to eliminate peridevice ...

In China, left atrial appendage (LAA) occlusion using the first-generation Watchman 2.5 device (Boston Scientific) is being performed with high procedural success plus low rates of periprocedural ...

FALL RIVER – Southcoast Health is enrolling patients in a new clinical trial to evaluate the use of a new heart ablation technology designed to treat atrial fibrillation. The community health system’s ...

CHICAGO -- For patients at high risk of stroke who underwent catheter-based atrial fibrillation ablation, left atrial appendage closure led to less bleeding compared with oral anticoagulation, the ...